YieldMax AI & Tech Portfolio Option Income ETF vs TransMedics Group Inc — how do they compare? YieldMax AI & Tech Portfolio Option Income ETF trades at $42.99 (market cap $135.69M), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 20.2× YieldMax AI & Tech Portfolio Option Income ETF's market cap, and YieldMax AI & Tech Portfolio Option Income ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax AI & Tech Portfolio Option Income ETF for 61 Days and TransMedics Group Inc for 24 Days on average.
| GPTY | TMDX | |
|---|---|---|
Market Cap | $135.69M | $2.74B |
Volume | 97,442 | 949,331 |
Sector | Income / Options Overlay | Health |
52-Week High | $50.52 | $150.42 |
52-Week Low | $34.73 | $61.99 |
Typical Hold Time | 61 Days | 24 Days |
Enterprise Value | — | $3.13B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →